This study determines whether quercetin supplementation reduces the inflammation and
oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small
study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Temple University
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) National Institutes of Health (NIH) Quercegen Pharmaceuticals